330 related articles for article (PubMed ID: 11120402)
1. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
Darmani NA
Neuropsychopharmacology; 2001 Feb; 24(2):198-203. PubMed ID: 11120402
[TBL] [Abstract][Full Text] [Related]
2. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.
Darmani NA
Pharmacol Biochem Behav; 2001; 69(1-2):239-49. PubMed ID: 11420092
[TBL] [Abstract][Full Text] [Related]
3. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
Janoyan JJ; Crim JL; Darmani NA
Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
[TBL] [Abstract][Full Text] [Related]
4. Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva).
Darmani NA; Crim JL
Pharmacol Biochem Behav; 2005 Jan; 80(1):35-44. PubMed ID: 15652378
[TBL] [Abstract][Full Text] [Related]
5. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2.
Darmani NA
Eur J Pharmacol; 2001 Oct; 430(1):49-58. PubMed ID: 11698062
[TBL] [Abstract][Full Text] [Related]
6. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
Darmani NA; Johnson JC
Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052
[TBL] [Abstract][Full Text] [Related]
7. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
[TBL] [Abstract][Full Text] [Related]
8. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids.
Darmani NA
J Pharmacol Exp Ther; 2002 Jan; 300(1):34-42. PubMed ID: 11752094
[TBL] [Abstract][Full Text] [Related]
9. Delta 9-tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew.
Ray AP; Griggs L; Darmani NA
Behav Brain Res; 2009 Jan; 196(1):30-6. PubMed ID: 18721829
[TBL] [Abstract][Full Text] [Related]
10. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.
Darmani NA; Janoyan JJ; Crim J; Ramirez J
Eur J Pharmacol; 2007 Jun; 563(1-3):187-96. PubMed ID: 17362921
[TBL] [Abstract][Full Text] [Related]
11. Additive antiemetic efficacy of low-doses of the cannabinoid CB(1/2) receptor agonist Δ(9)-THC with ultralow-doses of the vanilloid TRPV1 receptor agonist resiniferatoxin in the least shrew (Cryptotis parva).
Darmani NA; Chebolu S; Zhong W; Trinh C; McClanahan B; Brar RS
Eur J Pharmacol; 2014 Jan; 722():147-55. PubMed ID: 24157976
[TBL] [Abstract][Full Text] [Related]
12. Δ
Darmani NA; Belkacemi L; Zhong W
Eur J Pharmacol; 2019 Dec; 865():172806. PubMed ID: 31738934
[TBL] [Abstract][Full Text] [Related]
13. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
14. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
15. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
[TBL] [Abstract][Full Text] [Related]
16. Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.
Lichtman AH; Fisher J; Martin BR
Pharmacol Biochem Behav; 2001; 69(1-2):181-8. PubMed ID: 11420084
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse.
Lay L; Angus JA; Wright CE
Eur J Pharmacol; 2000 Mar; 391(1-2):151-61. PubMed ID: 10720647
[TBL] [Abstract][Full Text] [Related]
18. Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover.
Darmani NA; Janoyan JJ; Kumar N; Crim JL
Pharmacol Biochem Behav; 2003 Jul; 75(4):777-87. PubMed ID: 12957219
[TBL] [Abstract][Full Text] [Related]
19. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea.
Parker LA; Mechoulam R; Schlievert C; Abbott L; Fudge ML; Burton P
Psychopharmacology (Berl); 2003 Mar; 166(2):156-62. PubMed ID: 12528012
[TBL] [Abstract][Full Text] [Related]
20. SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study.
Bass CE; Griffin G; Grier M; Mahadevan A; Razdan RK; Martin BR
Pharmacol Biochem Behav; 2002 Dec; 74(1):31-40. PubMed ID: 12376150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
